Prostate Cancer Archives - Page 199 of 200 - Renal and Urology News

Prostate Cancer

Oral Platinum Analogue Looks Good

NEW YORK—Satraplatin, the first oral platinum analogue, is among the more promising second-line treatments for hormone-refractory prostate cancer (HRPC), a researcher said here at the 2006 Chemotherapy Foundation Symposium.

Drug Is Beneficial In Some PCa Cases

NEW YORK CITY—Results of the largest clinical trial ever conducted in non-metastatic prostate cancer suggest that bicalutamide (Casodex) added to standard care may improve overall survival in men with locally advanced disease undergoing radiotherapy.

New Medication Improves PCa Outcomes

NEW YORK—A high-dose oral formulation of calcitriol, called DN 101 and used in combination with docetaxel, is associated with longer survival in men with hormone-refractory prostate cancer (HRPC), according to a recent study.

Immunotherapy-Chemo Combo Possible

NEW YORK—Immunotherapy with sipuleucel-T followed by docetaxel chemotherapy may prolong survival in patients with androgen-independent prostate cancer (AIPC), a researcher reported here at the Chemotherapy Foundation Symposium.

Medication Protects Bone in PCa Patients

PHILADELPHIA—Prostate cancer patients treated with luteinizing hormone- releasing hormone (LHRH) have increased bone turnover and rapid bone loss within six months. A recent study suggests that this can be prevented with risedronate 35 mg once a week.

Next post in News